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Abstract
Background: Rift Valley fever virus (RVFV), a member of the genus Phlebovirus within the family Bunyaviridae, is a negative-
stranded RNA virus with a tripartite genome. RVFV is transmitted by mosquitoes and causes fever and severe hemorrhagic
illness among humans, while in livestock it causes fever and high abortion rates.
Methodology/Principal Findings: Sequence analysis showed that a wild-type RVFV ZH501 preparation consisted of two
major viral subpopulations, with a single nucleotide heterogeneity at nucleotide 847 of M segment (M847); one had a G
residue at M847 encoding glycine in a major viral envelope Gn protein, while the other carried A residue encoding glutamic
acid at the corresponding site. Two ZH501-derived viruses, rZH501-M847-G and rZH501-M847-A, carried identical genomic
sequences, except that the former and the latter had G and A, respectively, at M847 were recovered by using a reverse
genetics system. Intraperitoneal inoculation of rZH501-M847-A into mice caused a rapid and efficient viral accumulation in
the sera, livers, spleens, kidneys and brains, and killed most of the mice within 8 days, whereas rZH501-M847-G caused low
viremia titers, did not replicate as efficiently as did rZH501-M847-A in these organs, and had attenuated virulence to mice.
Remarkably, as early as 2 days postinfection with rZH501-M847-G, the viruses carrying A at M847 emerged and became the
major virus population thereafter, while replicating viruses retained the input A residue at M847 in rZH501-M847-A-infected
mice.
Conclusions/Significance: These data demonstrated that the single nucleotide substitution in the Gn protein substantially
affected the RVFV mouse virulence and that a virus population carrying the virulent viral genotype quickly emerged and
became the major viral population within a few days in mice that were inoculated with the attenuated virus.
Citation: Morrill JC, Ikegami T, Yoshikawa-Iwata N, Lokugamage N, Won S, et al. (2010) Rapid Accumulation of Virulent Rift Valley Fever Virus in Mice from an
Attenuated Virus Carrying a Single Nucleotide Substitution in the M RNA. PLoS ONE 5(4): e9986. doi:10.1371/journal.pone.0009986
Editor: Dong-Yan Jin, University of Hong Kong, Hong Kong
Received October 2, 2009; Accepted March 10, 2010; Published April 1, 2010
Copyright:  2010 Morrill et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants through the Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research,
National Institutes of Health (NIH) grant number U54 AI057156, and by NIH-NIAID-DMID-02-24 Collaborative Grant on Emerging Viral Diseases. TI, SW, and KT
were supported by the James W. McLaughlin Fellowship Fund. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cjpeters@utmb.edu (CJP); shmakino@utmb.edu (SM)
¤a Current address: National Institute of Infectious Diseases, Musahi-murayama, Tokyo, Japan
¤b Current address: The Department of Genetics, The Scripps Research Institute, La Jolla, California, United States of America
Introduction
Rift Valley fever virus (RVFV), a member of the genus
Phlebovirus within the family Bunyaviridae, causes periodic outbreaks
among livestock and humans in sub-Saharan African countries [1].
RVFV infection results in high mortality and abortion rates in
domestic ruminants with severe hepatic diseases. It also causes an
acute febrile myalgic syndrome, a hemorrhagic syndrome, ocular
disease, and encephalitis in humans [2,3]. Transmission of RVFV
to humans is primarily mosquito-borne or due to direct contact
with infected animal blood, tissues or products of abortion. Since
the late 1970s, several major outbreaks of Rift Valley fever have
occurred outside of sub-Saharan Africa, e.g., in Egypt [4],
Madagascar [5], Saudi Arabia, and Yemen [2,6]. The most
recent outbreak was reported in Kenya and resulted in a high
reported case-fatality ratio in infected humans [7].
RVFV has a single-stranded, tripartite RNA genome composed
of the L, M, and S segments. The L segment is of negative polarity
encoding the RNA-dependent RNA polymerase (L). The anti-viral-
sense M segment encodes two envelope glycoproteins, Gn and Gc,
and two accessory proteins,14-kDa NSm that suppresses virus-
induced apoptosis [8] and the 78-kDa protein. The S segment uses an
ambisense strategy for gene expression; a nonstructural protein, NSs,
is translated from viral-sense mRNA, while N protein is expressed
from anti-viral-sense mRNA [1]. N protein and L protein are essential
for viral RNA synthesis [1] and NSs protein suppresses host innate
immune functions by suppressing host gene expression [9], including
interferon-b [10], and promoting PKR degradation [11,12].
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e9986Experiments using reassortant viruses between an attenuated
MP-12 strain of RVFV and wild-type (wt) RVFV suggested that
RVFV virulence characteristics in the mouse are under polygenic
control [13]. Further studies using reassortant viruses between the
wt ZH548 strain of RVFV and an attenuated RVFV isolate clone
13, a plaque clone variant of the wt 74HB59 strain carrying a
deletion of 69% of the NSs gene [14], suggested that RVFV mouse
virulence is controlled by the S segment [15]. The importance of
NSs on viral virulence was confirmed by using a wt RVFV lacking
the entire NSs gene [16,17]. Studies using the wt RVFV lacking
the NSm gene showed that NSm also affected virus virulence in
rats [18]. In contrast, how Gn and Gc envelope proteins and L
protein contribute to viral virulence is unknown.
The present study revealed that wt RVFV ZH501 stock, which
was originally isolated from a patient during the 1977 outbreak of
RVFV in Egypt, was made up of two major virus populations with
single nucleotide substitution within the Gn gene and that a single
nucleotide difference in the Gn gene of wt RVFV substantially
affected viral mouse virulence. Furthermore, we observed a
remarkably rapid emergence and accumulation of the virulent-
type virus in the mice that had been inoculated with a low virulent-
type RVFV.
Results
Presence of two major viral subpopulations in wt ZH501
virus stock
Sequence analysis of the RT-PCR products of intracellular
ZH501-specific RNAs showed sequence homogeneity in all three
RNA segments, except for nucleotide 847 of the anti-viral sense M
segment RNA (M847), which consisted of a mixture of A and G
residues (Fig. 1). Of 35 independent, cloned RT-PCR products of a
region including M847, 18 clones and 17 clones had A and G,
respectively, at M847, which suggested to us that the ZH501 virus
stock consisted of roughly a 1-to-1 mixture of two major viral
subpopulations, one carrying A and the other carrying G at M847.
The virus carrying A residue at M847 encodes glutamic acid at amino
acid 277 (Glu277) of the Gn envelope protein, while that carrying the
G residue encodes glycine (Gly277). Sequence analysis of the cloned
PCR products also showed other sequence heterogeneities, including
silent mutations and those that altered amino acid sequences, within
t h eMs e g m e n t( d a t an o ts h o w n ) ,r e v e a l i n gaq u a s i s p e c i e sn a t u r eo f
the ZH501 virus stock. None of these other nucleotide heterogeneities
were shared among clones (data not shown).
Recovery of rZH501-M847-A and rZH501-M847-G from
cDNAs
T ok n o wt h ee f f e c t so ft h en u c l e o t i d ed i f f e r e n c ea tM 8 4 7o n
biological properties of the virus, we have recovered ZH501
carrying A at M847 (rZH501-M847-A) and that carrying G
(rZH501-M847-G) at the corresponding site using a reverse genetics
system of ZH501, in which endogenously expressed T7 polymerease
in BHK/T7-9 cells drives expression of viral RNAs and proteins
from the transfected plasmids. Sequence analysis of the entire L, M
and S RNA segments of rZH501-M847-A and rZH501-M847-G
revealed that both viruses had the expected primary sequences.
No substantial differences in the plaque sizes and morphologies
were detected among ZH501, rZH501-M847-G and rZH501-
M847-A in both Vero cells and MRC-5 cells (data not shown).
ZH501, rZH501-M847-G and rZH501-M847-A showed similar
replication kinetics in VeroE6 cells, mouse 3T3 cells and mouse
macrophage-derived J774.1 cells (Fig. 2), while titers of rZH501-
M847-G were roughly 10 times higher than those of rZH501-
M847-A in human lung fibroblast MRC-5 cells from 24 h to 72 h
p.i. (Fig. 2). Also there was a trend that CPE induced by rZH501-
M847-A was less prominent CPE than that induced by rZH501-
M847-G or ZH501 at a given time in all four cell lines (Fig. 2).
Unpaired-t-tests of three independent experiments examining the
replication kinetics of rZH501-M847-G and rZH501-M847-A in
MRC-5 cells from 0 h to 72 h p.i. revealed that the titer of
rZH501-M847-G was a significantly higher (P,0.01) than that of
rZH501-M847-A at 72 h p.i. (Fig. S1).
Mouse virulence of ZH501, rZH501-M847-A and rZH501-
M847-G
We examined the virulence of rZH501-M847-G, rZH501-
M847-A and ZH501 by intraperitoneal (i.p.) inoculation of 10
0,
10
1,1 0
2,1 0
3,1 0
4 or 10
5 plaque-forming units (PFU) of each virus
into five 5-week-old female CD-1 mice. Hanks’ balanced salt
solution (HBSS) was inoculated into control mice. These mice were
observed daily for 28 days p.i. (Fig. 3). None of the HBSS-
inoculated mice died, while inoculation of 10
2 to 10
5 PFU of
ZH501 resulted in the death of all of the mice within 13 days p.i.,
and one and three mice survived after inoculation of 10
1 and 10
0
PFU, respectively. All mice that were inoculated with 10
2 to 10
5
PFU of rZH501-M847-A died within 9 days p.i., and infection with
10
1 and 10
0 PFU resulted in the survival of one and four mice,
respectively. To our surprise, none of the rZH501-M847-G infected
mice died after inoculation of 10
0 to 10
2 PFU, four out of five mice
survived after inoculation of 10
4 and 10
3 PFU, and one mouse
survived after infection with 10
5 PFU. These data demonstrated
that ZH501 and rZH501-M847-A were highly virulent to mice,
whereas rZH501-M847-G had reduced mouse virulence.
To know the kinetics and titers of virus replication in various
organs, mice were inoculated i.p. with 10
5 PFU of rZH501-M847-
G, rZH501-M847-A, ZH501 and a mixture of 10
5 PFU of
rZH501-M847-G and the same titer of rZH501-M847-A. Virus
titers in livers, spleens, kidneys, sera and brains were determined
from 1 to 7 days p.i.; two to sixteen mice were used for each time
point (Fig. 4). The mice infected with ZH501, rZH501-M847-A,
and the mixture of rZH501-M847-G and rZH501-M847A
exhibited rapid, efficient virus replications in the liver early in
infection, high titers of viremia from 1 to 5 days p.i. and a gradual
increase of efficient virus replication in the brain, where the virus
titers exceeded 10
6 PFU/g at day 6 p.i. Efficient virus replication
Figure 1. Sequence analysis of the RT-PCR product of intracel-
lular viral-specific M RNA. The sequence of the viral-sense M segment
of ZH501 shows sequence heterogeneity, T and C, at M847 (asterisk).
doi:10.1371/journal.pone.0009986.g001
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day 8 p.i. The mice infected with rZH501-M847-G also showed
rapid virus replication in the liver, and yet the maximum liver
virus titer was approximately 10 times lower than that in the mice
infected with rZH501-M847-A, ZH501 and the mixture of
rZH501-M847-G and rZH501-M847-A. Also rZH501-M847-G
titers in the sera, kidneys, spleens and brains were substantially
lower than the virus titers in the corresponding organs of mice that
were infected with rZH501-M847-A, ZH501 and the mixture of
rZH501-M847-G and rZH501-M847-A. Unpaired-t-test results
showed that virus titers at days 1 to 3 in the serum and the liver,
days 2 to 4 in the spleen, days 2 to 5 in the kidney and days 2 to 6
in the brain of rZH501-M847-G-infected mice were statistically
lower (p,0.01) than the titers in the corresponding organs of
rZH501-M847-A-infected mice.
Neutralizing antibody titers in the infected mice
We next examined serum-neutralizing antibody titers in the
infected mice; ZH501 was used for the neutralizing antibody
assay. For each virus group, 19 to 23 mice were used. As shown in
Fig. 5, all mice that were inoculated i.p with 10
5 PFU of rZH501-
M847-A, ZH501 or a mixture of 10
5 PFU of rZH501-M847-G
and the same titer of rZH501-M847-A had less than detectable
levels of neutralizing antibodies until day 3 p.i. In contrast,
rZH501-M847-G-infected mice showed low, but detectable levels
of neutralizing antibodies early in infection; moreover, a low titer
of neutralizing antibody was detected as early as 1 day p.i. in some
of rZH501-M847-G-infected mice. Although neutralizing anti-
body titers increased in infected mice after day 5 p.i., there was a
trend that rZH501-M847-G-infected mice had higher neutralizing
antibody titers than did other infected mice. No neutralizing
antibodies were detected in sham-infected mice (data not shown).
Cross-neutralization analysis of rZH501-M847-A, rZH501-
M847-G and ZH501
We performed cross-neutralization assays to determine how
efficiently antiserum from rZH501-M847-G-infected mice and
that from rZH501-M847-A-infected mice could neutralize
Figure 2. Growth curve of ZH501, rZH501-847-A and rZH501-847-A in various cell lines. VeroE6 cells, NIH3T3 cells, J774.1 cells and MRC-5
cells were inoculated with ZH501, rZH501-847-A or rZH501-847-A at an moi of 0.02. Culture fluids were collected and virus titers were determined by
a plaque assay using VeroE6 cells. Virus growth curve of one representative experiment for each cell type is shown. Progression of CPE is represented
by the symbols: +, ++, +++ or +++. + = up to 25% of cell sheet affected showing cytolysis and swollen cells. ++ = up to 50% of cell sheet affected
showing lysed cells, floating cells and cell debris +++ = up to 75% of cell sheet affected showing significant cell lysis and increased amounts of cell
debris in culture fluid. ++++ = cell sheet destroyed with complete cytolysis.
doi:10.1371/journal.pone.0009986.g002
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M847-G serum demonstrating an 80% neutralizing antibody titer
(PRNT80 titer) of 1:640 to ZH501 and anti-rZH501-M847-A
serum demonstrating a PRNT80 titer of 1:80 to ZH501 were
obtained from rZH501-M847-G-infected mice and rZH501-
M847-A-infected mice, respectively. We used as controls, diluent,
normal mouse serum and convalescent goat anti-ZH501 serum
showing a PRNT80 titer of 1:5,120 to ZH501. In this assay, virus
titers were determined after overnight incubation of 100 mlo f
approximately 5.0 log10 PFU/ml of rZH501-M847-G, rZH501-
M847-A, and ZH501 with the same volume of undiluted
antiserum or diluent at 4uC (Table 1). Goat anti-ZH501 serum
efficiently neutralized all viruses, while incubation of rZH501-
M847-A and rZH501-M847-G with the normal mouse serum
resulted in small reductions of the virus titers. Anti-rZH501-M847-
G serum and anti-rZH501-M847-G serum neutralized the three
viruses at different efficiencies. The differences between the virus
titers (in log10PFU/ml) after incubation with each antiserum and
those after incubation with normal serum are shown within
parentheses in Table 1. The anti-rZH501-M847-G serum reduced
the titer of rZH501-M847-G by 1.63 log10 PFU/ml, while it
reduced the titer of rZH501-M847-A and ZH501 by 0.82 and
0.52 log10 PFU/ml, respectively. The anti-rZH501-M847-A
serum reduced the titers of rZH501-M847-A, rZH501-M847-G
and ZH501 by 1.60, 0.7, and 1.0 log10 PFU/ml, respectively.
These data demonstrated that mouse antiserum neutralized the
homologous virus to a similar extent, regardless of the PRNT80
titers, that antiserum neutralized the heterologous virus equally
but to a lesser degree than the homologous virus, and that anti-
rZH501-M847-A serum was able to neutralize the titer of ZH501
to a slightly greater degree than anti-rZH501-M847-G serum;
however, neither serum neutralized ZH501 equal to the
neutralization of their homologous viruses.
Histopathological and immunohistochemical (IHC)
examinations
To further understand the pathogenesis of rZH501-M847-G
and rZH501-M847-A, we performed histopathological and IHC
analyses of various organs of mice inoculated i.p. with 10
5 PFU of
rZH501-M847-G, rZH501-M847-A, ZH501 or a mixture of 10
5
PFU of rZH501-M847-G and the same titer of rZH501-M847-A
at various times p.i. (Figs. 6 and S2).
The livers of rZH501-M847-A-infected mice showed multifocal
hepatocellular necrosis with prominent aggregating mononuclear
inflammatory cells and sparsely scattered viral antigens throughout
the liver lobe as early as day 2 p.i. On day 3 p.i., most of the
hepatocytes were necrotic and positive for viral antigens (Fig. 6B).
Also, severe hemorrhages were noted throughout the lobe. After
day 4 p.i., the livers from mice examined showed less severe
hepatocellular damage than livers taken earlier, and the livers
examined on day 6 p.i. showed near complete resolution. ZH501-
infected mice presented with similar lesions and distribution of
viral antigens, and yet the progress of the lesions was somewhat
slower than those in rZH501-M847-A-infected mice (Fig. 6A).
Although rZH501-M847-G-infected mice had focal-to-multifocal
hepatocellular necrosis from days 2 to 4 p.i (Fig. 6C), they
exhibited mild hepatic lesions compared to ZH501-infected mice
and rZH501-M847-A-infected mice. Among mice inoculated with
the mixture of rZH501-M847-G and rZH501-M847-A, one
showed severe hepatic lesions like those of rZH501-M847-A-
infected mice, while others had mild hepatic lesions like that of
rZH501-M847-G-infected mice (data not shown).
The spleens of rZH501-M847-A-infected mice (Fig. 6E),
ZH501-infected mice (Fig. 6D) and mice inoculated with the
mixture of rZH501-M847-G and rZH501-M847-A (data not
shown) were characterized by a depletion of lymphocytes in the
white pulp from day 2 p.i. to day 5 or 6 p.i., with maximum
Figure 3. The virulence of ZH501, rZH501-M847-A and rZH501-M847-G in mice. Five-week-old female CD-1 mice were inoculated i.p. with
10
0,1 0
1,1 0
2,1 0
3,1 0
4 or 10
5 PFU of ZH501, rZH501-M847-A or rZH501-M847-G. Control mice were inoculated with HBSS. Mortality was recorded daily
for 28 days p.i. No mice died after 14 days p.i.
doi:10.1371/journal.pone.0009986.g003
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the white pulp from days 2 to 4 p.i. No lesions and viral antigens
were detected in the spleens of rZH501-M847-G-infected mice
(Fig. 6F).
All infected mice, except for rZH501-M847-G-infected mice,
had moderate, non-suppurative encephalitis throughout their
brains from day 5 p.i. (Fig. S2A). Viral antigens were detected
as early as day 2 p.i. in the endothelial cells of some mice. After
day 5 p.i., viral antigens were detected in neurons at the thalamus,
and spread to neurons of the surrounding areas (Fig. S2A, inset).
The lesions were diagnosed as mild meningitis or mild encephalitis
in the brains of rZH501-M847-G-infected mice (Fig. S2E), and
viral antigen was detected throughout the brains after day 7 p.i.
Kidneys of some of rZH501-M847-A-infected mice and the
mice infected with the mixture of rZH501-M847-G and rZH501-
M847-A showed pyknotic cells in glomeruli on day 3 p.i (Fig.
S2B). Most of the infected mice had viral antigens in the smooth
muscle of interlobular and arcuate arteries from day 2 p.i., and in
the mesangium of glomeruli on days 3 and 4 p.i (Fig. S2C, D).
Although no pathology was detected in the kidneys of the ZH501-
Figure 4. Virus titers in the various organs and serum of infected mice. Five-week-old, female CD-1 mice were inoculated i.p. with 10
5 PFU of
ZH501, rZH501-M847-A, rZH501-M847-G or a mixture of rZH501-M847-A and rZH501-M847-G. At 1 through 7 days p.i., serum, liver, spleen, kidney
and brain were collected from infected mice, and virus titers were individually determined by plaque assay. Two to sixteen mice were used for each
time point. In some cases, samples were collected from dead mice. They were: ZH501-infected mice–2 at day 3 p.i., 1 at 5 day p.i. and 1 at day 6 p.i.;
rZH501-M847-G-infected mice–1 at day 7 p.i.; rZH501-M847-A-infected mice–2 at days 2 and 4 p.i., 5 at day 3 p.i., 3 at day 5 p.i., and 4 at day 6 p.i.;
and rZH501-M847-G/rZH501-M847-A-co-infected mice–8 at day 3 p.i., 7 at day 6 p.i., and 2 at day 6 p.i.
doi:10.1371/journal.pone.0009986.g004
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mesangium of glomeruli and in the smooth muscle of interlobular
and arcuate arteries from days 3 to 7 p.i. The kidneys of rZH501-
M847-G-infected mice showed no pathology. Some of the infected
mice exhibited viral antigens from days 5 to 7 day p.i. in the
smooth muscle of interlobular and arcuate arteries (Fig. S2H),
whereas no viral antigens were detected in the glomeruli (Fig.
S2G).
In summary, there were rough correlations between the
presence of viral antigens and viral titers in the given organs,
and rZH501-M847-G-infected mice had delayed development of
lesions or showed less severe lesions than did other infected mouse
groups.
Emergence and accumulation of viruses carrying A
residue at M847 in rZH501-M847-G-infected mice
We next examined whether the viruses that accumulated in
infected mice retained the input-virus genome sequence at M847.
To this end, we took advantage of the presence of a naturally
occurring Sac I site (GAGCTC), which includes the A residue
(underlined) at M847 of rZH501-M847-A. Due to single
nucleotide substitution, the corresponding region of rZH501-
M847-G lacked this restriction enzyme site. Mice were infected i.p.
with 10
5 PFU of rZH501-M847-G or rZH501-M847-A (n=9 for
each group). Organs were isolated at various times p.i., and RT-
PCR products that included M847 were subjected to Sac I
digestion. For each virus group, we collected 3 livers at 4 day p.i., 3
spleens, 3 kidneys and 3 brains at day 6 p.i., and 3 brains at day
7 p.i. RT-PCR products of the expected size were obtained from
all samples of rZH501-M847-A-infected mice, and all were fully
susceptible to Sac I digestion (Fig. 7), demonstrating that
replicating rZH501-M847-A retained A residue at M847 in the
infected mice. We were unable to obtain RT-PCR products from
one spleen sample at day 6 p.i., one kidney sample at day 6 p.i.,
one brain sample at day 6 p.i., and one brain sample at day 7 p.i.
from rZH501-M847-G-infected mice (data not shown), probably
due to low virus titers in these samples. Two liver samples at day
4 p.i., were resistant to Sac I digestion (Fig. 7). Unexpectedly, the
RT-PCR products of one liver sample were a mixture of Sac I-
susceptible PCR product and Sac I-resistant products (Fig. 7) and
all other RT-PCR products, including two spleen samples at day
6 p.i., two brain samples at day 6 p.i., and two brains at day 7 p.i.
(data not shown) were susceptible to the Sac I digestion (Fig. 7).
These data strongly suggested an accumulation of rZH501-M847-
A-type virus carrying A residue at M847, in rZH501-M847-G
infected mice at 4 days p.i. in livers and 6 days p.i. in spleens and
brains.
To learn how quickly rZH501-M847-A-type virus accumulat-
ed in various organs of rZH501-M847-G-infected mice, we
inoculated 25 mice i.p. with 10
5 PFU of rZH501-M847-G, and
livers, spleens and brains were isolated every day through day
8 p.i. To eliminate the possible contamination by rZH501-M847-
A in the samples, rZH501-M847-A was not used in the BSL-4
laboratory during the experiments. For each sample, the virus
titers, production of RT-PCR products and susceptibilities of the
RT-PCR products to Sac I digestion are summarized in Fig. 8A
and the representative data concerning the Sac I digestion of the
RT-PCR products are shown in Fig. 8B. Most samples carrying
detectable levels of infectious viruses and many samples in which
virus titers were below the detection limit yielded the RT-PCR
products. Accumulation of rZH501-M847-A-type virus was
detected in the liver of a single mouse as early as 2 days p.i.
and rZH501-M847-A-type virus became the major virus
population in livers, spleens and brains from day 5 to 8 p.i. We
performed sequence analysis of some of the cloned RT-PCR
products to firmly establish the accumulation of rZH501-M847-
A-type virus in rZH501-M847-G-infected mice; the numbers of
the clones used for sequence analysis and the samples were: 20
clones from mouse 8b brain, 10 clones from mouse 6c spleen, 10
clones from mouse 7c brain, and 10 clones from mouse 7c spleen
(see Fig. 8A). Consistent with the data of Sac I digestion of the
RT-PCR products of these samples, all clones had A at M847.
These data unambiguously demonstrated that rZH501-M847-A-
type virus became the major virus population in rZH501-M847-
G-infected mice.
Figure 5. Neutralizing antibody titers in the infected mice.
Serum neutralizing antibody titers of five-week-old female CD-1 mice
inoculated i.p. with 10
5 PFU of ZH501, rZH501-M847-A, rZH501-M847-G
or a mixture of rZH501-M847-A and rZH501-M847-G. Dashed line
denotes the minimum neutralizing antibody detection level.
doi:10.1371/journal.pone.0009986.g005
Table 1. Cross-neutralization assays.
Virus Diluent Normal mouse serum Anti-rZH501-M847-G [1:640]* Anti-rZH501-M847-A [1:80] Goat anti-ZH501 [1:5,120]
rZH501-M847-G 4.70** 4.48 2.85 (1.63)*** 3.78 (0.70) ,0.7
rZH501-M847-A 4.57 4.30 3.48 (0.82) 2.70 (1.60) ,0.7
ZH501 4.90 5.00 4.48 (0.52) 4.00 (1.00) ,0.7
*PRNT80 titer to ZH501.
**Numbers represent virus titers in log10PFU/ml that were obtained after incubation with diluent, normal mouse serum or antisera.
***Numbers within the parenthesis represent differences between the virus titers in log10PFU/ml after incubation with each antiserum and those after incubation with
normal mouse serum.
doi:10.1371/journal.pone.0009986.t001
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population of rZH501-M847-A-type virus after infection with
rZH501-M847-G-type virus also occurred in cell culture, rZH501-
M847-G was independently passaged five times at a multiplicity of
infection (moi) of 0.01 and 1 in both VeroE6 cells and MRC-5
cells. RT-PCR products, including M847, were generated from
intracellular RNAs, extracted from cells infected with viruses at
passage levels 1 and 5, and subjected to Sac I digestion. We did not
observe the accumulation of rZH501-M847A-type virus after 5
passages of rZH501-M847-G in both cell types (data not shown),
demonstrating that the rZH501-M847-A-type virus did not
emerge after passages of rZH501-M847-G in cultured cells but
it became the major virus population in mice that were infected
with rZH501-M847-G.
Finally, we examined mouse virulence of rZH501-M847-A-
type virus that had accumulated in rZH501-M847-G-infected
mice by i.p. inoculation of 10
1,1 0
2,1 0
3,1 0
4 or 10
5 PFU of the
brain homogenates of 8b mouse (see Fig. 8A) into mice (n=5
for each dilution); RT-PCR analysis of mouse 8b brain extracts
revealed that rZH501-M847-A-type virus was the major virus
population, and sequence analysis of all 20 cloned RT-PCR
products of this brain extract showed that M847 was A.
Inoculation of 10
4 or 10
5 PFU of the recovered virus resulted
in the death of all mice within 7 days p.i., while 2 mice, 3 mice
and 4 mice survived after inoculation of 10
3 PFU, 10
2 PFU and
10
1 PFU of the virus, respectively (Fig. 9). The recovered
viruses had a higher mouse virulence than did rZH501-M847-
G, while they were not as virulent as rZH501-M847-A or
ZH501 (Fig. 3).
Discussion
A past report using reassortant viruses between an attenuated
MP-12 strain and wt RVFV suggested that RVFV virulence in
mouse is under polygenic control [13]. Past studies revealed that
the NSs gene, encoded in the S segment, and the NSm gene,
encoded in the M segment, both contribute to viral virulence
[16,17,18]. We presented here our findings that a single nucleotide
difference in M847 of the Gn gene of ZH501 substantially affected
virulence in mice, a result that further supports the notion that
RVFV virulence is under polygenic control [13].
Roughly a 1-to-1 mixture of the rZH501-M847-G-type virus
and rZH501-M847-A-type virus existed in the ZH501 virus stock.
Because the original ZH501 sample from a patient in the 1977
RVFV outbreak was not available, it is unclear whether high titers
of both rZH501-M847-G-type virus and rZH501-M847-A-type
virus replicated in the patient. We found that the rZH501-M847-
A-type virus became a major viral population in mice inoculated
with rZH501-M847-G, while viruses accumulated in mice
inoculated with rZH501-M847-A were the rZH501-M847-A-type
virus. Additionally, 38 of 39 isolates from wt RVFV thus far
reported were found to have A at M847 and carry Glu277 [19],
which is also encoded by rZH501-M847-A. These data suggest
that the rZH501-M847-A-type virus probably represented the
major virus population in the patient. However, it is possible that
rZH501-M847-G-type virus existed as an RVFV quasispecies in
the patient and affected the severity of the disease; quasispecies
have cooperative interactions to control viral pathogenesis [20].
Consistent with this notion, we found a lesser virulence in a virus
Figure 6. Histopathology and immunohistochemistry (IHC) of mice infected with ZH501 (A and D), rZH501-M847-A (B and E) and
rZH501-M847-G (C and F). (A) Liver histopathology and IHC (inset) from mice infected with ZH501 on day 3 p.i. The majority of the hepatocytes
were necrotic (hematoxylin and eosin staining) (magnification, 6200, inset:6400). (B) Liver histopathology and IHC (inset) from mice infected with
rZH501-M847-A on day 3 p.i. The samples showed severe hemorrhages in the livers due to disrupting hepatocytes (magnification, 6200, inset:
6400). (C) Liver histopathology and IHC (inset) from mice infected with rZH501-M847-G on day 3 p.i. Mice had focal necrosis in the liver
(magnification, 6200, inset: 6400). (D) Spleen histopathology and IHC (inset) from mice infected with ZH501 on day 3 p.i. Depletion of
lymphocytes in the white pulp was present (magnification, 6200, inset: 6400). (E) Spleen histopathology and IHC (inset) of mice infected with
rZH501-M847-A. The lesion was the same as that of ZH501-infected mice (magnification, 6200, inset: 6400). (F) Spleen histopathology and IHC
(inset) of mice infected with rZH501-M847-G (magnification, 6200, inset: 6400). No lesions or viral antigens were detected in the spleens of mice
infected with rZH501-M847-G.
doi:10.1371/journal.pone.0009986.g006
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virus and a minor population of rZH501-M847-G (Fig. 8A) and
obtained from a rZH501-M847-G-infected mouse brain at 8 days
p.i., than did rZH501-M847-A or ZH501 (Figs. 3 and 9). Although
the accumulation of rZH501-M847A-type virus did not occur
even after 5 passages of rZH501-M847-G in VeroE6 cells and
MRC-5 cells, we observed that rZH501-M847-G replicated to
higher titers than rZH501-M847-A in cultured cells (Figs. 2 and
S1). This trend in virus replication in vitro pointed to the
possibility that the rZH501-M847-G-type virus that was present as
a minor virus population in the patient could have amplified in cell
culture to become a major viral subpopulation in the ZH501 virus
stock that was generated in vitro.
The kinetics of virus accumulation in various organs in mice
inoculated with ZH501, rZH501-M847-A or rZH501-M847-G
showed that RVFV replicates in the liver early in infection. The
efficient replication of rZH501-M847-A and ZH501 in the liver
and in other initial target organs probably induced high viremia
titers that facilitated the spread of the virus to other organs,
including the spleen, kidneys and brain ultimately leading to
death of the animals. The virus titers in the liver of rZH501-
M847-G-infected mice at 2 days p.i. were roughly ten times
lower than those in the liver of rZH501-M847-A-infected mice
(Fig. 4). Likewise, virus titers in other organs and serum of the
rZH501-M847-G-infected mice were substantially lower than
those of the corresponding organs of rZH501-M847-A-infected
mice. The present data imply that the level of virus titers in the
initial target organ, e.g., the liver, at 2 to 3 days p.i. may
determine the severity and ultimate outcome of RVFV infection
in mice.
Although we have demonstrated the importance of single
nucleotide substitution at M847 of Gn protein for wt RVFV
mouse virulence, further studies are required to determine how
this single nucleotide substitution affected RVFV’s virulence. Past
studies showed that the gain-of-positive-charge mutations in the
flavivirus E protein [21,22,23] and the alphavirus E2 protein [24]
can enhance binding to negatively charged glycosaminoglycans
(GAG) and increase the efficiency of virus uptake into cultured
cells. However, the virulence of the variant viruses in mice is
reduced, as these variant viruses are rapidly cleared from the
circulatory system [22,24,25,26]. Probably, the gain-of-positive-
charge mutations in the envelope protein facilitates viral
adherence to GAGs present in blood cells and subsequent
reticuloendothelial system-mediated virus elimination from the
circulation. Likewise, rZH501-M847-A, which had a negatively
charged Glu277 of the Gn envelope protein, was highly virulent
for mice, while rZH501-M847-G carrying an uncharged Gly277
was substantially less virulent (Fig. 3). Furthermore, rZH501-
M847-A-infected mice showed higher viremia titers than rZH501-
M847-G-infected mice at 1-3 days p.i. (Fig. 4), but rZH501-M847-
G replicated at a higher titer than did rZH501-M847-A in MRC-5
cells (Fig. 2). Accordingly, it is possible that rZH501-M847-G
binds efficiently to GAGs in the circulation, resulting in low levels
of systemic infection, whereas rZH501-M847-A carrying Glu277
binds to GAGs less efficiently, resulting in high titers of viremia,
efficiently establishes a systemic infection that involves the CNS,
and kills the infected mice. The attenuated virus, MP-12,
developed by serial passage of the wt RVFV ZH548 strain in
the presence of 5-fluorouracil [27], carries A at M847 and encodes
Glu277, suggesting that the presence of Glu277 in Gn does not
always make RVFV virulent. The amino acid sequence of the M
segment of MP-12 differed from that of rZH501-M847-A by 5
amino acids. We suspect that a combination of some or all of these
mutated amino acids in the M segment contributed to the
attenuation of MP-12.
The present study showed the importance of the A nucleotide
at M847 of wt RVFV in mouse virulence, whereas it is unclear
whether this nucleotide also affects viral virulence in other
animals. Like rZH501-M847-G, one wt RVFV isolate 763/70,
which was obtained from an aborted bovine fetus in Zimbabwe in
1970 [28], has G at M847 and carries Gly 277 [19], while all the
rest of the wt RVFV isolates thus far sequenced carry A at M847
and encode Glu277 [19]. No information is available as to the
titers of 763/70 in different tissues of the aborted fetus and the
viremia status of its mother. Although we reported that pregnant
cows inoculated with ZH501 become febrile, have 2.3 to 4.0 log10
PFU/ml of viremia, and undergo abortion [29], the relationship
between level of viremia and abortion in cattle has not been
carefully examined yet. We observed that very low viremia can
result in abortion in experimentally infected sheep with ZH501 (J.
Morrill, unpublished data), and, hence, we speculate that
placental tissue in sheep and probably cattle may be exquisitely
sensitive to infection, and low titers of viremia can infect the
placenta at very low levels and gain access to the fetus. Virulence
of 763/70 in the bovine has not been experimentally tested and
763/70 differs from ZH501 at other genome regions. Accord-
ingly, the role of G at M847 of 763/70 in virus virulence for
bovine is unclear. Experimental infection of rZH501-M847-A
and rZH501-M847-G into domestic animals will show whether
the importance of the A nucleotide at M847 in viral virulence is
limited to the mouse model.
Figure 7. Sac I digestion of the RT-PCR products. Five-week-old
female CD-1 mice were infected i.p. with 10
5 PFU of rZH501-M847-G or
rZH501-M847-A. Total RNAs from 3 livers at 4 day p.i., 3 spleens at day
6 p.i., 3 kidneys at day 6 p.i., 3 brains at day 6 p.i., and 3 brains at day
7 p.i. were collected and subjected to RT-PCR analysis. In the samples
where RT-PCR products were obtained, RT-PCR products were digested
with Sac I and subjected to agarose gel electrophoresis. As controls,
PCR products that were obtained from plasmid encoding M segment of
rZH501-M847-A were digested with Sac I or incubated in the absence of
Sac I (Control).
doi:10.1371/journal.pone.0009986.g007
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CD-1 mice were infected i.p. with 10
5 PFU of rZH501-M847-G and liver, spleen and brain were collected every day from day 1 to day 8 p.i. Virus titer in
each sample was determined by a plaque assay. RT-PCR products were obtained from total RNAs in these samples and then subjected to Sac I
digestion. (A) Color and number in each box represent the genotype of major viruses and the virus titer in Log10PFU/g of tissue, respectively, in each
mouse. Color legend: G = genotype of rZH501-M847-G. A = genotype of rZH501-M847-A. G=A = a mixture of similar amounts of rZH501-M847-G
genotype and rZH501-M847-A genotype. G.A = viruses carrying the rZH501-M847-G genotype were more abundant than those carrying the
rZH501-M847-A genotype. A.G = viruses carrying the rZH501-M847-A genotype were more abundant than those carrying the rZH501-M847-G
genotype. Not decided = the major genotype of viruses was not determined due to weak RT-PCR signals. Not detected = RT-PCR products were not
obtained. (B) Agarose gel electrophoresis of the RT-PCR products that underwent SacI digestion. Only representative samples are shown. The mouse
identification number in the gel is shown in (A). Control = PCR products that were obtained from plasmid encoding M segment of rZH501-M847-A
were digested with Sac I or incubated in the absence of Sac I. N = Not detected. W = Not decided.
doi:10.1371/journal.pone.0009986.g008
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M847-A-type virus occurred in the mice inoculated with rZH501-
M847-G (Figs. 7 and 8). In the past, an experimental infection
using swine influenza virus resulted in a similarly rapid emergence
of a variant virus in infected hosts during single infections [30].
There are other examples of this type of quasispecies emergence
and fixation in vivo [31,32,33]. Although rZH501-M847-G was
rescued from cDNAs and direct sequencing of the M segment of
rZH501-M847-G did not show the presence of rZH501-M847-A-
type in the inoculum (data not shown), rZH501-M847-A-type
viruses might have been generated during T7 polymerase-
mediated primary transcription from the plasmid or during M
segment RNA replication and existed as one of a minor virus
population of ZH501-M847-G quasispecies in the inoculum.
Alternatively, rZH501-M847-A-type virus was generated by a
point mutation at M847 of the M segment in the rZH501-M847-
G-infected mice and became a major virus population as early as 2
days p.i. As discussed above, we speculate that rZH501-M847-A
may bind to GAGs less efficiently than does rZH501-M847-G.
This putative phenotype of rZH501-M847-A-type virus might
have prevented the efficient elimination of the virus from
reticuloendothelial systems, and facilitated continuous replication
and systemic infection.
We noted that neutralizing antibodies were rapidly elicited in
rZH501-M847-G-infected mice within 3 days p.i. (Fig. 5), during
which time most of the viruses retained the genotype of rZH501-
M847-G (Fig. 8). Because the importance of neutralizing
antibodies for the protection of animals from RVFV infection is
well documented [34,35,36,37,38,39,40,41,42], a rapid and
efficient generation of neutralizing antibodies probably contribut-
ed to low titers of viremia and prevention of systemic infection in
rZH501-M847-G-infected mice. It is interesting to note that the
antiserum neutralized the heterologous virus equally but to a lesser
degree than the homologous virus in the cross neutralization assay
(Table 1). These results were consistent with a report that the
region including Glu277 or Gly277 of Gn protein is a major
neutralizing epitope site [43]. It is likely that in the rZH501-M847-
G-infected mice, rZH501-M847-A-type virus emerged partly
because this virus was less susceptible to rapidly generated
neutralizing antibodies directed against rZH501-M847-G. We
further suspect that in the rZH501-M847-G-infected mice, newly
emerged rZH501-M847-A-type virus failed to continuously
replicate efficiently after 5 days p.i. in various organs primarily
due to an increase in the titers of neutralizing antibodies, resulting
in the survival of the mice. The virus titers in rZH501-M847-A-
inoculated mice were higher than those inoculated with rZH501-
M847-G in many organs during the first 4-5 days p.i., while the
neutralizing antibody titers tend to be higher in rZH501-M847-G-
inoculated mice than in rZH501-M847-A-inoculated mice (Fig. 5).
These data suggest that rZH501-M847-A replication might have
induced immunosuppression. This possibility was consistent with
the data that lymphocytes were depleted in the white pulp of mice
inoculated with rZH501-M847-A, but not those inoculated with
rZH501-M847-G, a finding probably due to apoptosis (Fig. 6).
Materials and Methods
Viruses and cells
The ZH501 strain of wt RVFV was obtained from the Special
Pathogens Branch at the Centers for Disease Control and
Prevention (CDC) (Atlanta, Georgia). RVFV ZH501 was
originally isolated from a patient during the 1977 outbreak of
RVFV in Egypt by inoculating the human specimen into suckling
mice brain. After amplification of the virus in the suckling mice
brain one more time, the ZH501 virus stock was generated after
two passages in FRhL cells and two passages in VeroE6 cells. The
Vero cell line and MRC-5 cell line were used for a viral plaque
assay as described previously [44]. All of the experiments that used
virulent ZH501 were performed in The Robert E. Shope, MD
BSL-4 Laboratory in the John Sealy Pavilion for Infectious
Diseases Research at The University of Texas Medical Branch at
Galveston, Texas.
Plasmid constructions
Standard molecular biological techniques were used to
construct plasmids. Total RNA of VeroE6 cells infected with
RVFV ZH501, which was obtained from Stuart Nichol at the
CDC, was used for first-strand cDNA synthesis. ZH501 virus stock
at CDC [16] and our ZH501 stock underwent the same passage
history. PCR fragments of full-length, antiviral-sense ZH501 S and
L-segments were cloned into a pProT7 plasmid [45], designated as
pProT7-wS(+) and pProT7-wL(+), respectively. The ZH501 M-
segment carrying G and A at nucleotide 847 of anti-viral-sense was
cloned into a pProT7 plasmid, designated as pProT7-wM(+)-
M847-G and pProT7-wM(+)-M847-A, respectively. The plasmids
expressing ZH501 N or L proteins under the control of T7 RNA
polymerase were reported previously [46]. The ORF of ZH501
glycoproteins, which carry G at nucleotide 847 of anti-viral-sense
M were cloned into the pCAGGS plasmid under chicken b-actin
promoter, designated as pCAGGS-G. All of the constructs were
confirmed to have the expected sequences.
Virus rescue
rZH501-M847-G, a recombinant ZH501 carrying G at
nucleotide 847 of anti-viral-sense M, was recovered by co-
transfection of pProT7-wS(+), pProT7-wM(+)-M847-G, pProT7-
wL(+), pT7-IRES-N, pT7-IRES-L and pCAGGS-G into BHK/
T7-9 cells by TransIT-LT1 (Mirus, Madison, WI), as described
previously [45]. rZH501-M847-A was recovered by co-transfec-
Figure 9. The virulence of rZH501-M847-A-type virus obtained
from the brain of rZH501-M847-G mouse. Five 5-week-old female
CD-1 mice were inoculated i.p. with 10
1,1 0
2,1 0
3,1 0
4 or 10
5 PFU of the
brain homogenates from the 8b mouse (Fig. 8A). Control mice were
inoculated with HBSS. Mortality was recorded daily for 28 days p.i. No
mice died after 9 days p.i.
doi:10.1371/journal.pone.0009986.g009
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pT7-IRES-N, and pT7-IRES-L into BHK/T7-9 cells. The culture
medium was replaced with fresh medium at 24 h post transfection.
At 5 days post transfection, the culture supernatants were
collected, clarified and then inoculated into VeroE6 cells. The
supernatant of infected VeroE6 cells at 3 days p.i. was collected
and used for titration of virus infectivity by plaque assay and for
the subsequent experiments. Sequence analysis of M segment
RNA confirmed the presence of the expected nucleotide at M847
in rZH501-M847-G and rZH501-M847-A.
Sequence analysis of the rescued viruses
Intracellular viral RNAs of infected MRC-5 cells served as the
source of sequence analysis. Most of the sequences of the L, M and
S RNA segments of rescued rZH501-M847-A and rZH501-
M847-A were determined by direct sequencing analysis of the
virus-specific RT-PCR products. For sequencing of the 59-end of
viral RNAs, free 59-phosphates in intracellular RNAs were
removed by calf intestinal alkaline phosphatase and then the
samples were treated with tobacco acid pyrophosphatase to
remove the cap structure. After ligation of the RNA adaptor to
uncapped RNA by using T4 RNA ligase, cDNA was synthesized
by employing an RLM-RACE kit (Ambion, Austin, TX) using
random primers. Amplicons were obtained by using a virus-
specific and an adaptor-specific primer and subjected to
sequencing analysis. For sequencing of the 39-end of viral RNAs,
a poly A tail was added to viral RNAs by using a Poly(A)
Polymerase Tailing Kit (Epicenter biotechnology, Madison, WI).
First-strand cDNA was synthesized from RNA containing a poly A
tail by using the 39Race adaptor (RLM-RACE kit, Ambion). The
cDNA was subjected to PCR with an adaptor-specific primer and
a virus-specific primer, and the amplicons were subjected to
sequence analysis.
Analysis of viral growth
VeroE6 cells, mouse 3T3 cells, mouse macrophage-derived
J774.1 cells and MRC-5 cells were infected with viruses at an moi
of 0.02 at 37uC for 1 h, and washed 3 times with PBS. Then
medium was added. Culture supernatants were harvested at
various times p.i., and the virus titer was measured by plaque
assay.
Virus plaque assays
Virus titers were determined by plaque assay in Vero cell
monolayers grown in 24-well plates. For the viral plaque assay,
serial tenfold dilutions of each specimen were prepared in HBSS
with 2% fetal bovine serum added (HBSS-FBS), and 50 ml of each
dilution was adsorbed on duplicate cell monolayers for 1 hour at
37uC. After 1 hour, the monolayers were overlaid with 0.6 ml of a
mixture of 1 part 1% agarose and 1 part 2X Eagle’s basal medium
with Earle’s salts, 17 mm HEPES, 8% fetal bovine serum, 100 U
of penicillin/ml and 100 mg of streptomycin sulfate/ml. After
incubation for 72 h at 37uC in a 5% CO2 atmosphere, each cell
monolayer was stained by adding 0.6 ml of a second overlay,
identical to the first, but containing 4% neutral red. After an
additional 24 h incubation, plaques were enumerated and viral
titers were calculated.
Virus inoculation into mice and collection of samples
from infected mice
Five-week-old female outbred CD-1 mice were purchased from
Charles River Laboratories (Wilmington, MA). The mice were
housed, 5 mice per cage, in micro-isolator cages, in a BSL-4
biological containment laboratory with a 12-h day-night photo-
period. Virus inocula were prepared in HBSS, pH 7.4, with no
supplements. Each mouse was inoculated i.p. with 0.1 ml of
inoculum in a tuberculin syringe fitted with a 26-gauge, 3/8- inch
needle. Moribund mice or mice pre-selected for euthanasia were
anesthetized with isoflurane, whole blood was collected via cardiac
puncture, and the mice were euthanatized by cervical dislocation.
Liver, spleen, and brain tissues were aseptically collected
immediately following euthanasia or as soon as dead mice were
discovered. All experiments were performed in accordance with
guidelines of the Institutional Animal Care and Use Committee of
the University of Texas Medical Branch and the recommendations
in the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council,
National Academy of Sciences, 1996). The facilities used are fully
accredited by the American Association for Accreditation of
Laboratory Animal Care.
Preparation of organ homogenates and sera
Tissues were prepared as 10% (w/v) homogenates in HBSS
supplemented with 10% heat-inactivated (56uC for 30 minutes)
fetal bovine serum and antibiotics (200 U/ml penicillin and
50 mg/ml streptomycin). Serum for virus and neutralizing
antibody assays was separated from whole blood by centrifugation
at 1,500 x g for 15 minutes and stored at -80uC until assayed.
Tissue homogenates were similarly clarified by centrifugation, and
supernatants were harvested and stored at 280uC until assayed.
Neutralizing antibody assays
Serum neutralizing antibody was determined using an 80%
plaque-reduction neutralization test. Serial fourfold dilutions of
serum were prepared in HBSS-FBS. An equal volume of the
ZH501 strain of RVFV suspension containing approximately 80
PFU/50 ml was added to each dilution. After incubation at 37uC
for 1 hr, 50 ml of each dilution was adsorbed on duplicate Vero
cell monolayers for 1 hr at 37uC and then overlaid with 0.6 ml of
the agarose-medium mixture used in the viral plaque assay. After
72 hr incubation at 37uC in a 5% CO2 atmosphere, each
monolayer received 0.6 ml of a second agarose containing neutral
red dye. Plaques were counted and an 80% reduction in the
number of plaques inoculated was used as the endpoint for virus-
neutralization titers.
Cross-neutralization assays
Anti-rZH501-M847-G serum demonstrating a PRNT80 titer of
1:640 to ZH501 was a mixture of the sera, each collected at days 6,
7 and 8 p.i. from eight rZH501-M847-G-infected mice. Similarly,
anti-rZH501-M847-A serum demonstrating a PRNT80 titer of 1:80
to ZH501 was a mixture of the sera collected at 6 days p.i. from
four rZH501-M847-A-infected mice. Diluent (HBSS-FBS) and
normal mouse serum served as negative controls, while convales-
cent goat anti-ZH501 serum showing a PRNT80 titer of 1:5,120 to
ZH501 served as a positive control. We incubated at 4uC overnight
vials containing 100 mlo fa p p r o x i m a t e l y5 . 0l o g 10 PFU/ml of
rZH501-M847-G, rZH501-M847-A or ZH501 combined with
100 ml of each serum sample or diluents. After incubation, virus
titers were determined by using viral plaque assays.
RNA extraction from organs
One hundred microliters of 10% tissue homogenate were mixed
with 900 ml of TRIzol reagent (Invitrogen, Carlsbad, CA). After
addition of 200 ml of chloroform, tubes were shaken vigorously by
hand and centrifuged at 15,000 rpm for 10 min at 4uC. Following
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and 500 ml of isopropanol was added to the tubes. Samples were
centrifuged at 15,000 rpm for 25 min at 4uC. RNA pellets were
washed with 75% ethanol and dried. Thirty microliters of RNase-
free water was added to dissolve the RNA pellet. The samples
were then treated with RQ1 RNase-Free DNase (Promega,
Madison, WI), and the RNAs were purified by addition with
phenol-chloroform.
RT-PCR and Sac I digestion
The total RNA of infected VeroE6 cells or mouse liver, spleen,
kidneys and brain were extracted with Trizol reagent (Invitrogen).
First-stranded cDNA was synthesized with a random hexamer by
RTG YouPrime RXN Beads (GE Healthcare, Bucks, UK)
according to the manufacturer’s instructions. PCR primers which
anneal to nucleotide 411 to nucleotide 430 (M430F: 59-ATG GCA
GGG ATT GCA ATG AC-39) or nt.1041 to 1060 (M1041R: 59-
ACT GCA AAG GGC ACA ACC TC-39) of anti-viral-sense M
were used for PCR reaction. PCR was performed for 30 cycles at
94uC for 40 sec, 55uC for 1 min, and 72uC for 1 min using the
Expand High Fidelity PCR System (Roche, Mannheim, Ger-
many). The PCR products were purified with QIAquick PCR
Purification Kit (Qiagen, Germantown, MD), digested with Sac I
and then separated on a 1% agarose gel.
Sequence of ZH501 M-segment
The PCR product consisting of a wild-type ZH501 M-segment
by M430F and M1041R was directly sequenced, or cloned into
pSTBlue-1 by AccepTor Vector Kits (Novagen, Darmstadt,
Germany) according to the manufacturer’s instruction. Thirty-
five clones were sequenced by T7 primer.
Histopathology and IHC examination
Specimens for histopathologic examination were collected in
10% neutral buffered formalin. The livers, spleens, kidneys, and
brains obtained from infected mice and control animals were
processed for histopathological and IHC examination as previ-
ously described [47]. Formalin-fixed and paraffin-embedded tissue
sections were subjected to hematoxylin and eosin (H&E) by
standard methods for evaluating histopathology and IHC staining
for detecting RVFV antigens, respectively. For detecting RVFV
antigens, the tissues were incubated with rabbit anti-N antibody
[48] (1:500). Color was developed by using the fuchsin+ substrate-
chromogen system (DAKO cytomation, Carpentaria, CA).
Supporting Information
Figure S1 Growth curve of rZH501-847-A and rZH501-847-A
in MRC-5 cells. MRC-5 cells were inoculated with rZH501-847-A
or rZH501-847-A at an moi of 0.02. Culture fluids were collected
and virus titers were determined by a plaque assay that used
VeroE6 cells. The results were obtained from three independent
experiments.
Found at: doi:10.1371/journal.pone.0009986.s001 (0.07 MB TIF)
Figure S2 Histopathology and IHC of mice infected with
rZH501-M847-A (A to D), and rZH501-M847-G (E to H). (A)
Brain of mouse infected with rZH501-M847-A on day 6 p.i. Viral
antigens were detected by IHC in the neurons (magnification,
6200, inset: 6400). (B) Glomerulus of the kidney in mouse
infected with rZH501-M847-A; some mice showed pyknotic cells
(arrow) in glomeruli (magnification,6600). (C, D) RVFV antigens
were detected by IHC in the glomeruli (C) and blood smooth
muscle of interlobular and arcuate arteries (D) of mice infected
with rZH501-M847-A (magnification, 6600). (E) Mice infected
with rZH501-M847-G had encephalitis on day 8 p.i. Viral
antigens were detected in the neurons by IHC (magnification,
6200, inset: 6400). (F) No lesions were found in the kidneys of
mice infected with rZH501-M847-G (magnification,6600). (G, H)
Viral antigens were detected in the smooth muscles of interlobular
and arcuate arteries (H); however antigens were not detected in
the glomeruli of mice infected with rZH501-M847-G (G)
(magnification, 6600).
Found at: doi:10.1371/journal.pone.0009986.s002 (2.55 MB TIF)
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